Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis

Table 3 Demographic, clinical, biochemical and histological characteristics of patients with nonalcoholic steatohepatitis under either pioglitazone or ursodeoxycholic acid

Variable	Pioglitazone group (n = 80)	UDCA group (n = 50)	P value
Age (yr)	47.6 ± 14.5	44.9 ± 14.5	0.303
Male gender	60 (75.0%)	30 (60.0)	0.071
Body mass index ≥ 25 kg/m2	66 (82.5%)	41 (82.0%)	0.942
Diabetes	38 (47.5%)	15 (30.0)	0.048a
Hypertension	29 (36.2%)	10 (20.0%)	0.049a
Hyperlipidemia	36 (45.0%)	26 (52.0%)	0.437
Fasting glucose (mg/dL)	121.3 ± 34.5	112.5 ± 24.1	0.090
HDL cholesterol (md/dL)	47.9 ± 10.0	47.7 ± 14.1	0.923
Triglycerides (mg/dL)	199.5 ± 147.7	185.9 ± 105.2	0.590
LDL cholesterol (mg/dL)	130.5 ± 29.4	136.4 ± 34.8	0.435
Alanine aminotransferase (U/L)	103.0 ± 76.1	74.6 ± 48.7	0.011a
Aspartate aminotransferase (U/L)	70.2 ± 40.5	65.7 ± 42.8	0.554
Gamma glutamyltransferase (U/L)	63.9 ± 61.3	62.3 ± 41.8	0.856
Platelet (× 1000/mm3)	229.8 ± 54.8	253.2 ± 54.4	0.019a
Albumin (g/dL)	4.5 ± 0.3	4.5 ± 0.3	0.866
Liver stiffness (kPa)	11.7 ± 4.8	10.5 ± 5.4	0.183
Stiffness IQR (kPa)	2.2 ± 4.7	1.4 ± 0.9	0.387
CAP (dB/m)	318.2 ± 37.9	319.3 ± 37.1	0.873
CAP IQR (dB/m)	25.2 ± 9.0	23.0 ± 10.1	0.216
Fibrosis score (Kleiner)			0.017a
F0	2 (2.5%)	9 (18.0%)
F1	41 (51.2%)	21 (42.0%)
F2	24 (30.0%)	15 (30.0%)
F3-4	13 (16.3%)	5 (10.0%)

Data are expressed as the mean ± standard deviation or median (range) or number (%),

^aP < 0.05. UDCA: Ursodeoxycholic acid; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; CAP: Controlled attenuation parameter; IQR: Interquartile range.